Brought to you by 
Series C round for Bind Biosciences garners $11mm
14 Jan 2010
Executive Summary
Bind Biosciences, which is using its Medicinal Nanoengineering technology to encapsulate medicines within nanoparticles for targeted drug delivery, brought in $11mm through its Series C financing. First-time backer DHK Investment led and was joined by some other new investors plus returning shareholders Polaris Venture Partners, Flagship Ventures, Arch Venture Partners, and NanoDimension. The round brings the total invested in the company to $29.5mm. Bind will use the money to advance its lead compound BIND014, a nano-formulated version of the cancer drug docetaxel, into human testing this year.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round for Bind Biosciences garners $11mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice